Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2025
0mins
Source: Newsfilter
Strategic Partnership Announcement: Abpro and Celltrion have partnered to develop and commercialize ABP-102/CT-P72, a bispecific T-cell engager targeting HER2-positive cancers, with promising preclinical data suggesting enhanced efficacy and safety compared to existing therapies.
Key Findings on Efficacy and Safety: ABP-102/CT-P72 demonstrates selective tumor killing, improved tumor growth inhibition, reduced cytokine release, and better tolerability in animal studies, indicating its potential as a safer alternative for treating HER2-driven cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
